Rifampicin resistance prevalence by gender
In this study we showed that GeneXpert identified 9 (5.9%) cases of rifampicin resistant TB out of the total (152) cases of TB in the year 2015 at Livingstone Central Hospital (LCH). The prevalence of rifampicin resistance in the current study is consistent with other published studies [12, 13]. However, a much lower and higher proportion was found in a study which was conducted in India [14] and in Ghana [3], respectively. The discrepancies maybe attributable to differences in sample sizes as well as poor record keeping and capturing of data alluded to in their studies as well as many other factors that may be unknown to us.
In this study, it was revealed that gender was not a factor when it comes to rifampicin resistance among our study population. This is similar to a study which was conducted in India [14], where it was found that the risk of rifampicin resistance among genders was the same. This could have been so due to the fact that men and women are exposed equally to factors that lead to rifampicin resistance in our settings, such as adherence and HIV. However, the low numbers of patients with rifampin resistance in this study may limit the comparison between males and females. Furthermore, we found no significant relationship between rifampicin resistance and all the demographic variables considered in this study. The male preponderance trend in TB in contrast to females suggests that there are more males than females who get diagnosed with TB. This trend is similar to other studies conducted in Nigeria where there were more (84, 60%) male patients against 56 (40%) females [15], in India [14] and in Zambia [1] where there were more male cases than female cases (P = 0.035). Further, this is very consistent with global trends in TB by gender [16].
Rifampicin resistance with HIV co-infected participants
In this study HIV co-infection was not found to be statistically significant with anti-TB drug resistance, as found in other studies [17] [18] however, the prevalence of co-infection with HIV among TB patients was very evident (98.3%, p < 0.001). This trend is very consistent with previous reports where two-thirds of Zambian TB patients notified to the NTP were co-infected with HIV [10]. The case of MDR-TB and co-infection with HIV may need further investigation as the cases of HIV negative participants were very few (2) in the sample population under our study. A study conducted in Zambia [13] that reviewed records from 2000 to 2011 found no data available on MDR-TB / HIV co-infections and this was attributed to inadequate reporting and recording.
On clinical basis, drug resistance is divided into two types namely: primary resistance and acquired resistance. Primary resistance occurs in individuals who have never been treated for TB and are infected with a resistant MTB strain. On the other hand, acquired resistance develops during therapy for TB. Though, it was beyond the scope of our study to ascertain the causes of drug resistance, it is well known from research in literature that TB resistance to drugs is multifactorial in nature and investigations into these factors must be specific to get a clear insight [19, 20].
Limitations
There was significant missing information on certain variables such as age, HIV status as well as rifampicin resistance status on patient records. Missing variables that are critical to finding the underlying causes of rifampicin resistance was a real limitation to our study. In this study we did not have contact with the patients hence certain important information such drug adherence, type of medications etc. which are important factors in the genesis of drug resistance, were not available for collection.
In this study, no information was available on drug resistance testing for the patients that tested rifampicin resistance positive on GeneXpert MTB/RIF to ascertain whether they were MDR-TB cases or rifampicin mono-resistant cases. This lack of information is very common in Zambian laboratories with few exceptions, such as the reference laboratories at the University Teaching Hospital, Tropical Disease Research Centre and the Chest Diseases Laboratory (National TB Reference Laboratory) [13]. Thus, it is possible that previous studies from this country under-estimated the prevalence of MDR-TB [13] and indicate that further investigations are warranted and illustrate the importance of improving the documentation of MDR-TB in Zambia.